Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - EAGLE PHARMACEUTICALS, INC. | exhibit32110k2020.htm |
| EX-31.2 - EX-31.2 - EAGLE PHARMACEUTICALS, INC. | exhibit31210k2020.htm |
| EX-31.1 - EX-31.1 - EAGLE PHARMACEUTICALS, INC. | exhibit31110k2020.htm |
| EX-23.1 - EX-23.1 - EAGLE PHARMACEUTICALS, INC. | exhibit23110k2020.htm |
| EX-21 - EX-21 - EAGLE PHARMACEUTICALS, INC. | exhibit21110k2020.htm |
| EX-10.30 - EX-10.30 FORM OF PSU MILESTONES - EAGLE PHARMACEUTICALS, INC. | exhibit1030formofpsumilest.htm |
| EX-10.29 - EX-10.29 FORM OF PSU TSR - EAGLE PHARMACEUTICALS, INC. | exhibit1029formofpsutsr.htm |
| 10-K - 10-K - EAGLE PHARMACEUTICALS, INC. | egrx-20201231.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
Eagle Pharmaceuticals, Inc.
Woodcliff Lake, New Jersey
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-234742 and 333-202592) and Form S-8 (Nos. 333-228876, 333-216839, 333-213683, 333-206729 and 333-194056) of Eagle Pharmaceuticals, Inc. (the “Company”) of our report dated March 2, 2020, relating to the consolidated financial statements which appears in this Form 10-K.
/s/ BDO USA, LLP
Woodbridge, New Jersey
March 4, 2021